AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9612624 — intervention group
Group type: EXPERIMENTAL
Intervention: Translaryngeal tracheostomy (TLT)
Number of subjects: 50
Study 9612624 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy (PT)
Number of subjects: 50
Study 7531852 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.1‐0.56 mg/70 kg)
Number of subjects: 7
Study 7531852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10‐32 mg/70 kg)
Number of subjects: 7
Study 7531852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (1‐6 mg/70 kg)
Number of subjects: 7
Study 7531852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30016133 — intervention group
Group type: COMPARATOR
Intervention: No diabetes/no foot ulcers (control)
Number of subjects: 150
Study 30016133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes but no foot ulcers
Number of subjects: 150
Study 30016133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and foot ulcers
Number of subjects: 150
Study 26948856 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day BUP (BUP4)
Number of subjects: 302
Study 26948856 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg/day BUP (BUP16)
Number of subjects: 302
Study 26948856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 302
Study 25110280 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin 300 mg (Treatment B)
Number of subjects: 37
Study 25110280 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin 300 mg (Treatment C)
Number of subjects: 37
Study 25110280 — intervention group
Group type: COMPARATOR
Intervention: Canagliflozin 150 mg (Treatment D)
Number of subjects: 37
Study 23778032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2g/day of ω‐3 polyunsaturated fatty acids (PUFA) for 12 weeks
Number of subjects: 81
Study 23778032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 23778032 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2g/day of ω‐3 polyunsaturated fatty acids (PUFA)
Number of subjects: 81
Study 19200979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix
Number of subjects: 89
Study 19200979 — intervention group
Group type: COMPARATOR
Intervention: Control (no ganirelix)
Number of subjects: 89
Study 19675104 — intervention group
Group type: EXPERIMENTAL
Intervention: P + 60 mg/d iron (Fe)
Number of subjects: 406
Study 19675104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe
Number of subjects: 406
Study 19675104 — intervention group
Group type: EXPERIMENTAL
Intervention: MM with added iron
Number of subjects: 406
Study 19675104 — intervention group
Group type: COMPARATOR
Intervention: P alone
Number of subjects: 406
Study 19675104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe and MM
Number of subjects: 406
Study 19675104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe with added MM
Number of subjects: 406
Study 16144766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary women
Number of subjects: 36
Study 16144766 — intervention group
Group type: EXPERIMENTAL
Intervention: Women extensor work
Number of subjects: 36
Study 16144766 — intervention group
Group type: EXPERIMENTAL
Intervention: Women flexor work
Number of subjects: 36
Study 16144766 — intervention group
Group type: EXPERIMENTAL
Intervention: Landing from a jump
Number of subjects: 36
Study 15240537 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional-dose anthracycline-based chemotherapy
Number of subjects: 739
Study 15240537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose anthracycline-based plus alkylating chemotherapy
Number of subjects: 739
Study 15240537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (surgical or chemotherapy regimen and histological type)
Number of subjects: 739
Study 15240537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (parameters predicting early failure)
Number of subjects: 739
Study 15240537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (parameters predicting early death)
Number of subjects: 739
Study 15240537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (independent predictors of early failure)
Number of subjects: 739
Study 15240537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (predictive model for early failure and death)
Number of subjects: 739
Study 11071027 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost
Number of subjects: 29
Study 11071027 — intervention group
Group type: COMPARATOR
Intervention: 0.50% timolol
Number of subjects: 29
Study 9054819 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered within 2 hours of symptom onset
Number of subjects: 2708
Study 9054819 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy administered after 4 to 6 hours of symptom onset
Number of subjects: 2708
Study 9054819 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy administered after 1 hour of arrival at hospital
Number of subjects: 2708
Study 8346772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 71
Study 8346772 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 71
Study 2427301 — intervention group
Group type: EXPERIMENTAL
Intervention: middle-molecular hydroxyethyl starch solution
Number of subjects: 30
Study 2427301 — intervention group
Group type: COMPARATOR
Intervention: isotonic sodium chloride solution
Number of subjects: 30
Study 30224909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient light exposure at 5 lux
Number of subjects: 60
Study 30224909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient light exposure at 10 lux
Number of subjects: 60
Study 30224909 — intervention group
Group type: COMPARATOR
Intervention: No ambient light exposure (control)
Number of subjects: 60
Study 26724180 — intervention group
Group type: COMPARATOR
Intervention: Developmental surveillance at 100% of well-child visits (WCVs) for non-English, non-Spanish group
Number of subjects: 450
Study 26724180 — intervention group
Group type: COMPARATOR
Intervention: Screened with a standardized developmental screening tool for non-English, non-Spanish group
Number of subjects: 450
Study 26724180 — intervention group
Group type: COMPARATOR
Intervention: Referral for diagnostic developmental evaluation
Number of subjects: 450
Study 26724180 — intervention group
Group type: COMPARATOR
Intervention: Developmental surveillance at 100% of WCVs for Spanish-speaking group
Number of subjects: 450
Study 26724180 — intervention group
Group type: COMPARATOR
Intervention: Screened with a standardized developmental screening tool for Spanish-speaking group
Number of subjects: 450
Study 24912459 — intervention group
Group type: EXPERIMENTAL
Intervention: Online parenting skills training (n=20)
Number of subjects: 37
Study 24912459 — intervention group
Group type: COMPARATOR
Intervention: Access to Internet resources on managing brain injury (n=17)
Number of subjects: 37
Study 24912459 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-income parenting skills group
Number of subjects: 37
Study 24912459 — intervention group
Group type: COMPARATOR
Intervention: High-income Internet resource group
Number of subjects: 37
Study 23248896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-directional power toothbrush (Oral-B Professional Deep Sweep + SmartGuide TRICLEAN 5000)
Number of subjects: 128
Study 23248896 — intervention group
Group type: COMPARATOR
Intervention: Sonic control toothbrush (Philips Sonicare FlexCare)
Number of subjects: 128
Study 20633268 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental expressed emotion (EE)
Number of subjects: 0
Study 20633268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low parental warmth
Number of subjects: 0
Study 20633268 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-related cortisol reactivity
Number of subjects: 0
Study 20633268 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental EE
Number of subjects: 0
Study 18385186 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-oriented intervention (multi-faceted training for nurses about falls, risk factors, and environmental modifications)
Number of subjects: 10
Study 18385186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10
Study 15798899 — intervention group
Group type: EXPERIMENTAL
Intervention: High case volume hospitals
Number of subjects: 536
Study 15798899 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium case volume hospitals
Number of subjects: 536
Study 15798899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low case volume hospitals
Number of subjects: 536
Study 12193675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 64
Study 12193675 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 64
Study 12193675 — intervention group
Group type: COMPARATOR
Intervention: Supine position with increased carbohydrate intake
Number of subjects: 64
Study 12193675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position with increased carbohydrate intake
Number of subjects: 64
Study 12193675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position during postprandial minutes 10-100
Number of subjects: 64
Study 10071299 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for BRCA1 and BRCA2 offered free of charge
Number of subjects: 200
Study 7564132 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium) 3 x 500 mg orally for 2 years
Number of subjects: 74
Study 7564132 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 74
Study 7564132 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium)
Number of subjects: 74
Study 2201161 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate solution
Number of subjects: 0
Study 2201161 — intervention group
Group type: COMPARATOR
Intervention: 2% methylcellulose solution (placebo)
Number of subjects: 0
Study 7299760 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg 3 days/week)
Number of subjects: 32
Study 7299760 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (250 mg increments at 2-3 monthly intervals)
Number of subjects: 32
Study 30359616 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly improving ARDS (defined by extubation or Pao2:Fio2 ratio > 300 on the first study day)
Number of subjects: 4361
Study 30359616 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly improving ARDS
Number of subjects: 4361
Study 30359616 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive variables for rapidly improving ARDS
Number of subjects: 4361
Study 27893550 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of dexamethasone applied to the masseter muscle after surgery
Number of subjects: 30
Study 27893550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 30
Study 26035702 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐PC (albumin-bound paclitaxel + carboplatin), N=265
Number of subjects: 546
Study 26035702 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐PC (albumin-bound paclitaxel + carboplatin)
Number of subjects: 546
Study 26035702 — intervention group
Group type: COMPARATOR
Intervention: sb‐PC (solvent‐based paclitaxel + carboplatin), N=281
Number of subjects: 546
Study 23807094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no antibiotics)
Number of subjects: 152
Study 23807094 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 152
Study 23807094 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in sputum purulence
Number of subjects: 152
Study 23807094 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP concentration ≥ 40 mg/L
Number of subjects: 152
Study 23807094 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthonisen criteria
Number of subjects: 152
Study 23807094 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthonisen criteria + CRP level
Number of subjects: 152
Study 21155632 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH ER (up to 1 mg/kg per day)
Number of subjects: 162
Study 21155632 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH ER
Number of subjects: 162
Study 21155632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 19951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily human insulin mix 30/70
Number of subjects: 117
Study 19951567 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily insulin lispro low mix 25
Number of subjects: 117
Study 19951567 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 117
Study 19951567 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 117
Study 19951567 — intervention group
Group type: COMPARATOR
Intervention: Human insulin mix 30/70
Number of subjects: 117
Study 19951567 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro low mix 25
Number of subjects: 117
Study 17715274 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 44
Study 17715274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15605661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent dilatation (EDD) in patients with PAPS
Number of subjects: 31
Study 15605661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-independent dilatation (EID) in patients with PAPS
Number of subjects: 31
Study 15605661 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent dilatation (EDD) in patients with arterial involvement (17 patients)
Number of subjects: 31
Study 15605661 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-dependent dilatation (EDD) in controls
Number of subjects: 31
Study 11275673 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 30
Study 11275673 — intervention group
Group type: COMPARATOR
Intervention: Erythritol
Number of subjects: 30
Study 9215204 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal acoustic stimulation test
Number of subjects: 577
Study 9215204 — intervention group
Group type: COMPARATOR
Intervention: Mock test (control)
Number of subjects: 577
Study 7679583 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg three times a day after a 6.25 mg test dose, n = 32)
Number of subjects: 100
Study 7679583 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg three times a day, n = 31)
Number of subjects: 100
Study 7679583 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 100
Study 3115916 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized educational program
Number of subjects: 300
Study 3115916 — intervention group
Group type: EXPERIMENTAL
Intervention: Group administered educational program
Number of subjects: 300
Study 3115916 — intervention group
Group type: COMPARATOR
Intervention: Information/attention control
Number of subjects: 300
Study 3115916 — intervention group
Group type: COMPARATOR
Intervention: Data-only control condition
Number of subjects: 300
Study 30593463 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg, three times a day)
Number of subjects: 45
Study 30593463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 28791362 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD treatment group
Number of subjects: 60
Study 28791362 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-COPD group
Number of subjects: 60
Study 28791362 — intervention group
Group type: COMPARATOR
Intervention: COPD control group
Number of subjects: 60
Study 26401255 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV protease inhibitors (HIV‐PIs) saquinavir and ritonavir (SQV+RIT)
Number of subjects: 0
Study 23467813 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12 supplementation (2 mg of folic acid and 400 μg of vitamin B12 daily for 16 weeks)
Number of subjects: 140
Study 23467813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 23467813 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12 supplementation
Number of subjects: 140
Study 20970351 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/formoterol/budenoside (GR1)
Number of subjects: 46
Study 20970351 — intervention group
Group type: COMPARATOR
Intervention: tiotropium/formoterol (GR2)
Number of subjects: 46
Study 19477811 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured meditation program (2 1/2 hours once a week for 7 weeks)
Number of subjects: 0
Study 19477811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17079524 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterstrain treatment
Number of subjects: 20
Study 17079524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15271741 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 30
Study 15271741 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 30
Study 11311835 — intervention group
Group type: EXPERIMENTAL
Intervention: Career counseling program consisting of individual counseling and group sessions using cognitive and behavioral intervention techniques over a 6-month period.
Number of subjects: 171
Study 11311835 — intervention group
Group type: COMPARATOR
Intervention: Self-initiated preventive measures among control group dentists (N=35).
Number of subjects: 171
Study 11311835 — intervention group
Group type: COMPARATOR
Intervention: Control group dentists who did not undertake preventive action (N=31).
Number of subjects: 171
Study 9564119 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CLO) (50 mg/day) + Dexamethasone (DEX) (2 mg/day)
Number of subjects: 160
Study 9564119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg/day) + Tropisetron (TRO) (5 mg/day)
Number of subjects: 160
Study 9564119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg/day) + Tropisetron (5 mg/day) + Dexamethasone (2 mg/day)
Number of subjects: 160
Study 9564119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (TRO) (5 mg/day)
Number of subjects: 160
Study 8035384 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting subgroup
Number of subjects: 42
Study 8035384 — intervention group
Group type: COMPARATOR
Intervention: Pain attention subgroup
Number of subjects: 42
Study 2721537 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-dergocrine 4 mg/day for 3 weeks
Number of subjects: 0
Study 5483323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate administered with tetracycline
Number of subjects: 0
Study 5483323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate administered with oxytetracycline
Number of subjects: 0
Study 5483323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate administered with methacycline
Number of subjects: 0
Study 5483323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate administered with doxycycline
Number of subjects: 0
Study 5483323 — intervention group
Group type: EXPERIMENTAL
Intervention: Small doses of iron taken simultaneously with tetracycline
Number of subjects: 0
Study 31531555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal warm-up (VWU)
Number of subjects: 0
Study 31531555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal cool-down (VCD)
Number of subjects: 0
Study 31531555 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - vocal rest
Number of subjects: 0
Study 28637741 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 300
Study 28637741 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 300
Study 25848072 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood-derived products (ABPs)
Number of subjects: 604
Study 25848072 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (CSs)
Number of subjects: 604
Study 25848072 — intervention group
Group type: COMPARATOR
Intervention: Shock-wave (SW) therapy
Number of subjects: 604
Study 22968670 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported pendulum (ISP)
Number of subjects: 30
Study 22968670 — intervention group
Group type: COMPARATOR
Intervention: Zygoma anchorage system (ZAS)
Number of subjects: 30
Study 21351220 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 310
Study 21351220 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 310
Study 19487995 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises along with usual treatment for pain
Number of subjects: 0
Study 19487995 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment for pain (Control)
Number of subjects: 0
Study 19487995 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep breathing exercises
Number of subjects: 0
Study 17185043 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT), 2 sets of 8 repetitions of 11 exercises, twice a week for 8 weeks, RPE of 15-18
Number of subjects: 0
Study 15161785 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.75 mg
Number of subjects: 193
Study 15161785 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.45 mg
Number of subjects: 193
Study 15161785 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (1-4 mg)
Number of subjects: 193
Study 11339099 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium substitution
Number of subjects: 220
Study 11339099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 220
Study 9549925 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPCT
Number of subjects: 25
Study 10150392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine
Number of subjects: 80
Study 10150392 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 80
Study 3353525 — intervention group
Group type: EXPERIMENTAL
Intervention: thoracic EA with bupivacaine (0.5%) in combination with a light general anesthesia
Number of subjects: 31
Study 3353525 — intervention group
Group type: EXPERIMENTAL
Intervention: neuroleptanalgesia (NLA)
Number of subjects: 31
Study 3353525 — intervention group
Group type: COMPARATOR
Intervention: halothane anesthesia
Number of subjects: 31